Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Has Consensus Target Price of $8.75

Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $8.75.

TKNO has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alpha Teknova in a report on Wednesday, November 4th. Jefferies Financial Group started coverage on shares of Alpha Teknova in a research note on Thursday, September 17th. They issued a “buy” rating and a $9.00 price objective on the stock. Wall Street Zen upgraded shares of Alpha Teknova from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research upgraded Alpha Teknova to a “hold” rating in a research note on Thursday, August 6th. Finally, BTIG Research raised Alpha Teknova from a “neutral” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Tuesday, August 11th.

Alpha Teknova Price Performance

Shares of TKNO opened at $8.73 on Friday. The company has a market cap of $549.12 million, a price-to-earnings ratio of -30.10 and a beta of 0.96. Alpha Teknova has a 1-year low of $1.91 and a 1-year high of $9.48. The company’s fifty day simple moving average is $7.79 and its 200 day simple moving average is $5.04. The company has a current ratio of 3.56, a quick ratio of 3.48 and a debt-to-equity ratio of 0.22.

Alpha Teknova (NASDAQ:TKNO) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $12.70 million during the quarter, compared to the consensus estimate of $11.71 million. Alpha Teknova had a negative net margin of 34.76% and a negative return on equity of 24.95%. On average, research analysts forecast that Alpha Teknova will post -0.26 earnings per share for the current fiscal year.

Institutional Trading of Alpha Teknova

Several large investors have recently bought and sold shares of the business. Deutsche Bank AG acquired a new stake in shares of Alpha Teknova during the 2nd quarter valued at $62,000. Ieq Capital LLC acquired a new stake in Alpha Teknova in the second quarter valued at $62,000. R Squared Ltd acquired a new stake in Alpha Teknova in the first quarter valued at $42,000. Susquehanna International Group LLP acquired a new stake in Alpha Teknova in the second quarter valued at $115,000. Finally, Fielder Capital Group LLC acquired a new stake in shares of Alpha Teknova in the second quarter valued at about $143,000. 13.81% of the stock is owned by institutional investors and hedge funds.

Alpha Teknova Company Profile

Alpha Teknova, Inc. is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing. Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.